Navamedic ASA risk profile
30 Normal where most of the sector sits
Measured 21 October 2026 from NAVA's filed statements. Recomputed nightly.
30 (Normal), driven by Market expectation at 68, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 68 | Stretched | Stable | Drawdown from the 52-week high — 48.5% |
| Operating pressure | 57 | Elevated | Worsening | Costs outgrowing revenue — +3.5 percentage points |
| Cash conversion | 34 | Normal | Worsening | Free-cash-flow margin — 4.1% |
| Leverage and coverage | 29 | Normal | Worsening | Net debt to EBITDA — 3.01x |
| Competitive position | 8 | Contained | Stable | Revenue-growth gap against peers — +37.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.